8
Oct
2024

MSN Laboratories

Exhibitor at CPHI Milan 2024 stand 24C1, Integrated Pharma
About Us

MSN Laboratories was founded in 2003 and is one of the fastest growing pharmaceutical manufacturers of APIs and finished dosages in India. We have 18 API and 6 Finished dosage facilities & an integrated R&D Center located in Hyderabad.

Our state-of-the-art facilities are accredited by  USFDA, EU:GMP, WHO:Geneva, PIC/S, ANVISA, Invima and many other global approvals. With a product portfolio covering 35 major therapies including Oncology, MSN reaches out to millions of people in over 100 countries across North America, Europe, Latin America, CIS, Middle East, Africa & Asia.  

Our strengths are our world-class facilities, innovation driven R&D, strong IPM, commitment to quality, efficient supply chain and a team with proven track record.

MSN is proud to launch 1st-in-the-World Generics for 16 state-of-the-art-medicines at affordable prices; file 920+ patents, 1171+ DMFs/CEPs , 2000 Formulation Dossiers & more than 40 ANDAs.  With annual capacities over 12 Billion units for the Oral Solids, Injectibles and Oncologics, we support 300 partners across 100 countries in the API and Formulations business.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2015
    On CPHI since
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 24C1, Integrated Pharma

MSN Laboratories Resources (1)

  • MSN corporate overview

    Brochure MSN corporate overview

    MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.